Brief: Simcere Pharmaceutical Says Approval For Marketing Of Quviviq ® In China By NMPA
20/06/2025 16:05
June 20 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK: APPROVAL FOR MARKETING OF QUVIVIQ ® IN CHINA BY NMPA Further company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660